person · Reporting owner

LEIDEN JEFFREY M

Disclosed activity across 5 companies

Tapewire entity: 14913
SEC CIK: 0001242825

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Odyssey Therapeutics, Inc.ODTX · Entity 4850	Director	May 07, 2026	May 12, 2026
QUEST DIAGNOSTICS INCDGX · Entity 2118	Director	May 29, 2018	May 30, 2018
Revolution Healthcare Acquisition Corp.REVH · Entity 135631	Director	March 17, 2021	March 17, 2021
VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875	Director · Executive Chairman	February 24, 2026	February 26, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Odyssey Therapeutics, Inc.

Report date May 07, 2026 · Filed May 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	270,198	Reported balance After 2026-05-08 transaction · row 1 1 source row Row 1 · 2026-05-08 · Purchase · Acquired 5,000 · Balance 270,198
Common StockSEC Table I · non-derivative	IndirectSee footnote	31,644	Last balance in matching sequence After 2026-05-11 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 2 · 2026-05-11 · Conversion · Acquired 28,698 · Balance 28,698 F1: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration. F2: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F3: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. Row 3 · 2026-05-11 · Exercise / conversion · Acquired 2,963 · Balance 31,661 F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. Row 4 · 2026-05-11 · Tax withholding · Disposed 17 · Balance 31,644 F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. F6: Pursuant to the terms of the warrants, the Issuer withheld 17 warrant shares to pay the exercise price in connection with the net exercise. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2026-05-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-05-11 · Conversion · Disposed 79,166 · Balance 0 F1: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration. F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2026-05-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-05-11 · Conversion · Disposed 100,000 · Balance 0 F2: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities.
Series D Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2026-05-11 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-05-11 · Conversion · Disposed 96,002 · Balance 0 F3: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-05-06	Direct	626,220	Reported balance After 2026-05-07 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-05-07 · Grant · Acquired 626,220 · Balance 626,220 F8: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.
Series D Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.10	IndirectSee footnote	0	Reported balance After 2026-05-11 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-05-11 · Exercise / conversion · Disposed 28,800 · Balance 0 F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities.

Filing footnotes · ownership attribution and instrument terms

F1: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration.

F2: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.

F3: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.

F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities.

F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis.

F6: Pursuant to the terms of the warrants, the Issuer withheld 17 warrant shares to pay the exercise price in connection with the net exercise.

F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering.

F8: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.

QUEST DIAGNOSTICS INC

Report date May 29, 2018 · Filed May 30, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	6,000	Reported balance After 2018-05-29 transaction · row 1 1 source row Row 1 · 2018-05-29 · Sale · Disposed 1,644 · Balance 6,000

Revolution Healthcare Acquisition Corp.

Report date March 17, 2021 · Filed March 17, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B common stockSEC Table I · non-derivative	IndirectBy Racing Beach Ventures LLC	7,500	Reported balance Holding disclosure · report date 2021-03-17 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 7,500 F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-253729), as amended, under the heading "Description of Securities - Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the Issuer after the consummation of the Issuer's initial business combination. F2: Shares held directly by Racing Beach Ventures LLC. The Reporting Person is a managing member of Racing Beach Ventures LLC and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-253729), as amended, under the heading "Description of Securities - Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the Issuer after the consummation of the Issuer's initial business combination.

F2: Shares held directly by Racing Beach Ventures LLC. The Reporting Person is a managing member of Racing Beach Ventures LLC and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

VERTEX PHARMACEUTICALS INC / MA

Report date February 24, 2026 · Filed February 26, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	34,797	Reported balance After 2026-02-24 transaction · row 1 1 source row Row 1 · 2026-02-24 · Tax withholding · Disposed 3,547 · Balance 34,797
Common StockSEC Table I · non-derivative	Indirect401(k)	440	Reported balance Holding disclosure · report date 2026-02-24 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 440

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ABBOTT LABORATORIES

Report date March 24, 2006 · Filed March 28, 2006

Section 16 reporting ended · disclosed 2006-03-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common shares without par valueSEC Table I · non-derivative	Direct	209,401	Ending reported balance After 2006-03-24 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2006-03-24 · Tax withholding · Disposed 91,846 · Balance 309,401 Row 2 · 2006-03-24 · Disposition to issuer · Disposed 100,000 · Balance 209,401
Common shares without par valueSEC Table I · non-derivative	IndirectProfit Sharing Trust	635	Reported balance Holding disclosure · report date 2006-03-24 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 635 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of March 24, 2006.

Filing footnotes · ownership attribution and instrument terms

F1: Balance in the Abbott Laboratories Stock Retirement Trust as of March 24, 2006.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 04, 2019 Filed Feb 6, 2019 21:47 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,300	$184.99	$240,487.00	Disclosure SEC source: 0001209191-19-007764 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,815 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $184.99 (range $184.49 to $185.38). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
June 22, 2018 Filed Jun 26, 2018 21:18 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option (Right to Buy) · Derivative	106,500	$0.00 Strike: $83.36	$0.00	Disclosure SEC source: 0001209191-18-039523 · doc4.xml · derivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 106,500 shares Expires 2023-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document
June 22, 2018 Filed Jun 26, 2018 21:18 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	140,211	$160.00	$22,433,760.00	Disclosure SEC source: 0001209191-18-039523 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,049 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document
June 22, 2018 Filed Jun 26, 2018 21:18 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	106,500	$83.36	$8,877,840.00	Disclosure SEC source: 0001209191-18-039523 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 29, 2018 Filed May 30, 2018 20:38 UTC	QUEST DIAGNOSTICS INC DGX · Entity 2118	SaleCommon Stock	1,644	$105.61	$173,622.84	Disclosure SEC source: 0001022079-18-000137 · wf-form4_152771268719626.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Read SEC document
May 15, 2018 Filed May 17, 2018 21:22 UTC	QUEST DIAGNOSTICS INC DGX · Entity 2118	GrantCommon Stock	1,644	$0.00	$0.00	Disclosure SEC source: 0001022079-18-000115 · wf-form4_152659215558567.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,644 F1 · security: Represents an award of restricted share units. Read SEC document
February 12, 2018 Filed Feb 14, 2018 23:06 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	200	$153.89	$30,778.00	Disclosure SEC source: 0001209191-18-010105 · doc4.xml · nonDerivative · entry 6 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,658 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $153.89 (range $153.88 to $153.89). Read SEC document
February 12, 2018 Filed Feb 14, 2018 23:06 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	2,000	$153.29	$306,580.00	Disclosure SEC source: 0001209191-18-010105 · doc4.xml · nonDerivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,858 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $153.29 (range $152.88 to $153.84). Read SEC document
February 12, 2018 Filed Feb 14, 2018 23:06 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,200	$152.40	$182,880.00	Disclosure SEC source: 0001209191-18-010105 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,858 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $152.40 (range $151.85 to $152.81). Read SEC document
February 12, 2018 Filed Feb 14, 2018 23:06 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	10,100	$151.23	$1,527,423.00	Disclosure SEC source: 0001209191-18-010105 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,058 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $151.23 (range $150.83 to $151.82). Read SEC document
February 12, 2018 Filed Feb 14, 2018 23:06 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	4,305	$150.44	$647,644.20	Disclosure SEC source: 0001209191-18-010105 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,158 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $150.44 (range $149.79 to $150.76). Read SEC document
February 12, 2018 Filed Feb 14, 2018 23:06 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	6,100	$149.22	$910,242.00	Disclosure SEC source: 0001209191-18-010105 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,463 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $149.22 (range $148.77 to $149.74). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
February 06, 2018 Filed Feb 8, 2018 23:07 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantStock Option (Right to Buy) · Derivative	73,046	$0.00 Strike: $155.57	$0.00	Disclosure SEC source: 0001209191-18-008526 · doc4.xml · derivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,046 Underlying: Common Stock · 73,046 shares Expires 2028-02-05 F3 · derivative.exercise_date: This option vests in 16 quarterly installments from 2/6/2018. Read SEC document
February 06, 2018 Filed Feb 8, 2018 23:07 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	31,498	$0.00	$0.00	Disclosure SEC source: 0001209191-18-008526 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,563 F2 · shares: Restricted stock unit award that vests in three equal installments on 2/17/2019, 2/17/2020 and 2/17/2021. Read SEC document
February 06, 2018 Filed Feb 8, 2018 23:07 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	50,568	$0.00	$0.00	Disclosure SEC source: 0001209191-18-008526 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,065 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/03/2017 that contained both performance-vesting and service-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2018. The earned performance shares remain subject to the service-vesting requirements and will vest in three equal installments on 2/10/2018, 2/10/2019 and 2/10/2020. Read SEC document
January 16, 2018 Filed Jan 17, 2018 21:45 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option (Right to Buy) · Derivative	55,313	$0.00 Strike: $45.11	$0.00	Disclosure SEC source: 0001209191-18-003981 · doc4.xml · derivative · entry 10 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,313 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document
January 16, 2018 Filed Jan 17, 2018 21:45 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option (Right to Buy) · Derivative	44,250	$0.00 Strike: $48.74	$0.00	Disclosure SEC source: 0001209191-18-003981 · doc4.xml · derivative · entry 9 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,250 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document
January 16, 2018 Filed Jan 17, 2018 21:45 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	7,995	$159.39	$1,274,323.05	Disclosure SEC source: 0001209191-18-003981 · doc4.xml · nonDerivative · entry 7 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,497 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $159.39 (range $159.18 to $159.75). Read SEC document
January 16, 2018 Filed Jan 17, 2018 21:45 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	17,918	$158.79	$2,845,199.22	Disclosure SEC source: 0001209191-18-003981 · doc4.xml · nonDerivative · entry 6 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,492 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $158.79 (range $158.18 to $159.16). Read SEC document
January 16, 2018 Filed Jan 17, 2018 21:45 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	11,471	$157.67	$1,808,632.57	Disclosure SEC source: 0001209191-18-003981 · doc4.xml · nonDerivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,410 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $157.67 (range $157.18 to $158.17). Read SEC document
January 16, 2018 Filed Jan 17, 2018 21:45 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	19,808	$156.62	$3,102,328.96	Disclosure SEC source: 0001209191-18-003981 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,881 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $156.62 (range $156.18 to $157.17). Read SEC document
January 16, 2018 Filed Jan 17, 2018 21:45 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	42,371	$155.77	$6,600,130.67	Disclosure SEC source: 0001209191-18-003981 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,689 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $155.77 (range $155.18 to $156.17). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
January 16, 2018 Filed Jan 17, 2018 21:45 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	55,313	$45.11	$2,495,169.43	Disclosure SEC source: 0001209191-18-003981 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 16, 2018 Filed Jan 17, 2018 21:45 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	44,250	$48.74	$2,156,745.00	Disclosure SEC source: 0001209191-18-003981 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 11, 2017 Filed Dec 11, 2017 23:30 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	5,198	$143.39	$745,341.22	Disclosure SEC source: 0001209191-17-065094 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,497 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $143.39 (range $142.90 to $143.85). Read SEC document
December 11, 2017 Filed Dec 11, 2017 23:30 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	12,134	$142.21	$1,725,576.14	Disclosure SEC source: 0001209191-17-065094 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,695 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $142.21 (range $141.86 to $142.79). Read SEC document
December 11, 2017 Filed Dec 11, 2017 23:30 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	87,578	$141.35	$12,379,150.30	Disclosure SEC source: 0001209191-17-065094 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,829 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $141.35 (range $140.86 to $141.85). Read SEC document
December 11, 2017 Filed Dec 11, 2017 23:30 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	20,090	$140.31	$2,818,827.90	Disclosure SEC source: 0001209191-17-065094 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,407 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $140.31 (range $139.85 to 140.84). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
August 04, 2017 Filed Aug 8, 2017 20:27 UTC	QUEST DIAGNOSTICS INC DGX · Entity 2118	SaleCommon Stock	296	$106.66	$31,571.06	Disclosure SEC source: 0001022079-17-000166 · wf-form4_150222401171554.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $106.657 to $106.66. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
July 31, 2017 Filed Aug 2, 2017 20:56 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option (Right to Buy) · Derivative	11,063	$0.00 Strike: $45.11	$0.00	Disclosure SEC source: 0001209191-17-047139 · doc4.xml · derivative · entry 6 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,313 Underlying: Common Stock · 11,063 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document
July 31, 2017 Filed Aug 2, 2017 20:56 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	700	$154.05	$107,835.00	Disclosure SEC source: 0001209191-17-047139 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,392 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $154.05 (range $153.91 to $154.27). Read SEC document
July 31, 2017 Filed Aug 2, 2017 20:56 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	5,000	$153.24	$766,200.00	Disclosure SEC source: 0001209191-17-047139 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,092 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $153.24 (range $152.79 to $153.78). Read SEC document
July 31, 2017 Filed Aug 2, 2017 20:56 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	5,363	$152.25	$816,516.75	Disclosure SEC source: 0001209191-17-047139 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,092 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $152.25 (range $151.79 to 152.77). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
July 31, 2017 Filed Aug 2, 2017 20:56 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	11,063	$45.11	$499,051.93	Disclosure SEC source: 0001209191-17-047139 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 27, 2017 Filed Jul 31, 2017 20:42 UTC	QUEST DIAGNOSTICS INC DGX · Entity 2118	SaleCommon Stock	1,304	$108.73	$141,782.62	Disclosure SEC source: 0001022079-17-000161 · wf-form4_150153371086914.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,296 F1 · price: This transaction was executed in multiple trades at prices ranging from $108.729 to $108.73. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
July 21, 2017 Filed Jul 22, 2017 00:04 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	5,058	$162.08	$819,800.64	Disclosure SEC source: 0001209191-17-046027 · doc4.xml · nonDerivative · entry 9 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,392 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $162.08 (range $161.92 to $162.45). Read SEC document
July 21, 2017 Filed Jul 22, 2017 00:04 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	17,255	$161.43	$2,785,474.65	Disclosure SEC source: 0001209191-17-046027 · doc4.xml · nonDerivative · entry 8 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,450 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $161.43 (range $160.92 to $161.91). Read SEC document
July 21, 2017 Filed Jul 22, 2017 00:04 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	900	$160.42	$144,378.00	Disclosure SEC source: 0001209191-17-046027 · doc4.xml · nonDerivative · entry 7 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,705 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $160.42 (range $159.90 to $160.86). Read SEC document
July 21, 2017 Filed Jul 22, 2017 00:04 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	3,500	$159.34	$557,690.00	Disclosure SEC source: 0001209191-17-046027 · doc4.xml · nonDerivative · entry 6 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,605 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $159.34 (range $158.89 to $159.77). Read SEC document
July 21, 2017 Filed Jul 22, 2017 00:04 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	4,837	$158.46	$766,471.02	Disclosure SEC source: 0001209191-17-046027 · doc4.xml · nonDerivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,105 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $158.46 (range $157.88 to $158.86). Read SEC document
July 21, 2017 Filed Jul 22, 2017 00:04 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	700	$157.42	$110,194.00	Disclosure SEC source: 0001209191-17-046027 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,942 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $157.42 (range $156.81 to $157.71). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
July 19, 2017 Filed Jul 22, 2017 00:04 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option (Right to Buy) · Derivative	73,750	$0.00 Strike: $48.74	$0.00	Disclosure SEC source: 0001209191-17-046027 · doc4.xml · derivative · entry 12 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,250 Underlying: Common Stock · 73,750 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document
July 19, 2017 Filed Jul 22, 2017 00:04 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option (Right to Buy) · Derivative	110,624	$0.00 Strike: $45.11	$0.00	Disclosure SEC source: 0001209191-17-046027 · doc4.xml · derivative · entry 11 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,376 Underlying: Common Stock · 110,624 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document
July 19, 2017 Filed Jul 22, 2017 00:04 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	184,374	$161.00	$29,684,214.00	Disclosure SEC source: 0001209191-17-046027 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,642 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. Read SEC document
July 19, 2017 Filed Jul 22, 2017 00:04 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	73,750	$48.74	$3,594,575.00	Disclosure SEC source: 0001209191-17-046027 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 19, 2017 Filed Jul 22, 2017 00:04 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	110,624	$45.11	$4,990,248.64	Disclosure SEC source: 0001209191-17-046027 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 02, 2017 Filed Jun 5, 2017 22:03 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option (Right to Buy) · Derivative	124,601	$0.00 Strike: $29.98	$0.00	Disclosure SEC source: 0001209191-17-037920 · doc4.xml · derivative · entry 6 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 124,601 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document
June 02, 2017 Filed Jun 5, 2017 22:03 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option (Right to Buy) · Derivative	22,500	$0.00 Strike: $53.85	$0.00	Disclosure SEC source: 0001209191-17-037920 · doc4.xml · derivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2021-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document
June 02, 2017 Filed Jun 5, 2017 22:03 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	147,101	$129.50	$19,049,579.50	Disclosure SEC source: 0001209191-17-037920 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,642 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document
June 02, 2017 Filed Jun 5, 2017 22:03 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	124,601	$29.98	$3,735,537.98	Disclosure SEC source: 0001209191-17-037920 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.